Retatrutide 20MG (GLP-3 "RET")
Retatrutide is a synthetic investigational peptide designed as a triple receptor agonist targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. For Retatrutide, each vial is labeled 20MG, molecular formula C221H342N46O68, molecular weight approx. 4,731 Da, CAS 2381089-83-2.
Published laboratory work with Retatrutide has examined triple incretin receptor pharmacology, metabolic signaling pathway, glucose homeostasis investigations. Each lot is manufactured under sterile conditions, lyophilized in single-use research vials, and labeled with its production lot for traceability.
Supplied for in-vitro laboratory research use only. Not for human or veterinary consumption, administration, diagnostic or therapeutic use.
Retatrutide 20MG research vial of a tri-agonist peptide studied for GIP, GLP-1 and glucagon receptor activity in laboratory models.
Browse all GLP class research peptides.
Background reading on this compound in the ENOS Lab Notes: Retatrutide Phase 3 Update: Triple-Agonist Class Advances and The GLP Peptide Family Explained.
Background reading: the Retatrutide compound reference, how to read a certificate of analysis, why purity and identity are separate tests and storage and handling guidance.
- Ships from Arizona
- Free shipping through Nov 14
- Zelle, Venmo, Cash App, USDT
These products are sold strictly for in-vitro laboratory research and are not intended for human consumption, diagnosis, treatment, or any therapeutic use. Purchaser must be 18 years of age or older and confirms they are a qualified researcher.
Compound identity
Listed on the storefront as GLP-3 "RET". The compound information for this research vial is below.
- Compound name
- Retatrutide
- Also known as
- Retatrutide, LY3437943, GLP-3 RET, Triple agonist peptide
- Molecular formula
- C221H342N46O68
- Molecular weight
- Approximately 4,731 Da
- CAS number
- 2381089-83-2
- Vial size
- 20MG
Product Information
Research DatasheetProduct Overview
Retatrutide is a synthetic investigational peptide designed as a triple receptor agonist targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. It is widely studied in laboratory settings to investigate metabolic signaling, energy homeostasis, glucose regulation, lipid metabolism, and receptor pharmacology. This lyophilized research peptide is manufactured under sterile conditions. For laboratory research use only. Not for human or veterinary use.
Molecular Profile
Research Applications
- ◆Triple incretin receptor pharmacology
- ◆Metabolic signaling pathway research
- ◆Glucose homeostasis investigations
- ◆Energy expenditure studies
- ◆Lipid metabolism research
- ◆Endocrine signaling investigations
- ◆Receptor binding and activation studies
- ◆Metabolic disease laboratory models
- ◆Peptide pharmacokinetics and stability research
- ◆Drug discovery and translational peptide research
Quality Standards
Lab documentation: available on request, info@enosusa.com
For in-vitro research use only. Not for human consumption, diagnosis, or treatment.
Retatrutide 20MG research vial of a tri-agonist peptide studied for GIP, GLP-1 and glucagon receptor activity in laboratory models. All ENOS research vials are lyophilized, sealed under sterile conditions, and shipped with cold-chain packaging where appropriate.
- ◆Metabolic pathway research
- ◆Multi-receptor agonism
- ◆Investigational compound
You may also like
GLP-3 "RET" · 10MG
Retatrutide 10MG research vial, GIP, GLP-1 and glucagon receptor triple agonist.
GLP-3 "RET" · 30MG
Retatrutide 30MG research vial, GIP, GLP-1 and glucagon receptor triple agonist.
GLP-2 "TIRZ" · 10MG
Tirzepatide 10MG research vial, GIP and GLP-1 receptor dual agonist.
GLP-2 "TIRZ" · 20MG
Tirzepatide 20MG research vial, GIP and GLP-1 receptor dual agonist.